Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication SILIQ ® (brodalumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. FDA label
Also known as SILIQ, AMG 827
Brodalumab · 4 trials · 20 indications
ACR20 is used as a measurement of the proportion of subjects who are reaching a 20% improvement of tender an swollen joint counts. The higher percent of subjects reaching a higher improvement percentage shows greater success.
The number of adverse events of each grade that occur and the number of adverse events attributed to brodalumab, as per the Common Terminology Criteria for Adverse Events version 5 (CTCAE v5).
The percentage of patients whose primary irAE severity decreased by \>1 grade per CTCAE criteria from study completion to treatment discontinuation.
Pharmacokinetic parameter estimates after a 210 mg dose of brodalumab, and after two 210 mg doses of brodalumab delivered subcutaneously as a single prefilled syringe (PFS) injection
Pharmacokinetic parameter estimates after a 210 mg dose of brodalumab, and after two 210 mg doses of brodalumab delivered subcutaneously as a single prefilled syringe (PFS) injection
Midazolam pharmacokinetic parameter estimates after single oral dose of Midazolam 2 mg on Day 1 and Day 9 and a single administration of Brodalumab 210 mg on Day 2 with PK sampling collected on Day 30
Midazolam pharmacokinetic parameter estimates after single oral dose of Midazolam 2 mg on Day 1 and Day 9 and a single administration of Brodalumab 210 mg on Day 2 with PK sampling collected on day 30
Midazolam pharmacokinetic parameter estimates after single oral dose of Midazolam 2 mg on Day 1 and Day 9 and a single administration of Brodalumab 210 mg on Day 2
| Arm | Type | Description |
|---|---|---|
| 210 mg brodalumab | EXPERIMENTAL | Administered via subcutaneous injections. |
| 140 mg brodalumab | EXPERIMENTAL | Administered via subcutaneous injection. |
| Placebo | PLACEBO_COMPARATOR | Administered via subcutaneous injection until week 24. |
| brodalumab to treat irAEs in patient with solid tumors | EXPERIMENTAL | Brodalumab 210 mg subcutaneous injection on weeks 0, 1, 2 followed by administration every 2 weeks until week 24 |
| Brodalumab (single 1.5mL pre-filled syringe) | EXPERIMENTAL | A single 210 mg subcutaneous (SC) dose of Brodalumab administered using a single 1.5mL pre-filled syringe injection |
| Brodalumab (2 pre-filled syringes [1.0mL + 0.5mL]) | EXPERIMENTAL | A single 210 mg subcutaneous (SC) dose of Brodalumab administered using 2 (1.0mL + 0.5mL) pre-filled syringe injections |
| Brodalumab 140mg SC | EXPERIMENTAL | open label, all subjects receive brodulamab |
| Midazolam (MDZ) 2mg oral, Brodalumab 210mg SC | EXPERIMENTAL | MDZ 2mg oral (Day 1 and Day 9), Brodalumab 210mg SC (Day 2) |
| Name | Type | Description |
|---|---|---|
| 210 mg brodalumab | DRUG | 210 mg brodalumab administered via subcutaneous injection. |
| 140 mg brodalumab | DRUG | 140 mg brodalumab administered via subcutaneous injection. |
| Placebo | DRUG | Placebo administered via subcutaneous injection until week 24. |
| Brodalumab | DRUG | Brodalumab 210 mg subcutaneous injection |
| CT scan | RADIATION | CT scans within 4 weeks of starting brodalumab and every 3 months during the study for tumor assessment |
Inclusion Criteria: Subjects has a diagnosis of psoriatic arthritis (by the Classification of Psoriatic Arthritis criteria (CASPAR), with ≥ 3 tender and ≥ 3 swollen joints (excluding distal interphalangeal joints). Subjects must have at least 1 psoriatic skin lesion. Exclusion Criteria: • -Subjec...
Top 11 of 12 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 6 | PHASE3 | Risankizumab, Adalimumab, Lutikizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 4 | PHASE3 | Zasocitinib |
| Johnson & Johnson | JNJ | 9 | PHASE3 | Guselkumab, Icotrokinra, Ustekinumab, JNJ-88545223 |
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Deucravacitinib |
| Amgen Inc. | AMGN | 3 | PHASE3 | Apremilast, Apremilast IR |
| MoonLake Immunotherapeutics Class A | MLTX | 3 | PHASE3 | Sonelokimab |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Ixekizumab, Tirzepatide |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY002-072 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE1 | Secukinumab |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Pfizer Inc. | PFE | 2 | - | tofacitinib |
Brodalumab is an investigational biologic developed by Bausch Health Companies Inc. (ticker BHC). It is being studied in oncology and immunology settings, including breast cancer, psoriasis, and psoriatic arthritis. Brodalumab is a large-molecule biologic rather than a small-molecule drug.
Brodalumab targets IL17RA, the interleukin-17 receptor A. It acts as an antagonist at this receptor, blocking signaling through the IL-17 pathway. This receptor-level mechanism distinguishes brodalumab from agents that bind the IL-17 ligand itself.
Brodalumab is developed by Bausch Health Companies Inc., which trades under the ticker BHC. The company is associated with the clinical development program covering the drug's oncology and immunology indications, including breast cancer, psoriasis, and psoriatic arthritis.
Brodalumab is in Phase 1 development according to its current program status. It is investigational and is being evaluated in clinical trials rather than positioned as an approved therapy. Its studied indications include breast cancer, psoriasis, and psoriatic arthritis.
Brodalumab trials include NCT06673329, a recruiting Phase 1 study of brodalumab in immune-related adverse events across multiple solid tumors, and NCT02173392, a completed Phase 1 bioequivalence study in psoriasis. A completed Phase 3 study, NCT02024646, evaluated brodalumab in psoriatic arthritis with 484 participants.